Mosapride/Probiotics

N/A

Report date: 2026/02/12 20:00:14

Base Information

Drug NameMosapride/Probiotics
Drug Alias NameMosapride / Bacillus subtilis/Streptococcus faeciumMedirac/mosaprideMosapride/Bacillus subtilis / Enterococcus faeciumHCP-0613
ClassificationSmall molecules
Mechanisms of ActionSerotonin 4 (5-HT4) receptor agonists
TargetsSerotonin 4 (5-HT4) receptor
Therapy Area/IndicationsIrritable Bowel SyndromeSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes Mosapride (Korea United Pharm)
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFudan University
Inactive CompaniesHanmi Pharmaceutical Co Ltd
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsIrritable Bowel Syndrome

Other Information

ATC CodeN/A
Related LinksN/A